SuperworthMannkind market cap MNKD
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Oct 23, 2026
- $1B
- Highest close in our data
- $4.1B
- Jun 2014
Mannkind is worth $1B at the close on Oct 23, 2026, at $3.19 a share.
That is down 37% over the last year and down 13% over five years.
Its highest close in our data was $4.1B in Jun 2014.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $1B | $702.5M | $1.8B | −42% |
| 2025 | $1.8B | $1.1B | $1.8B | −5% |
| 2024 | $1.9B | $884.2M | $2B | +92% |
| 2023 | $981.3M | $924.6M | $1.5B | −29% |
| 2022 | $1.4B | $684.9M | $1.4B | +26% |
| 2021 | $1.1B | $730.4M | $1.4B | +51% |
| 2020 | $728M | $199.5M | $919.9M | +157% |
| 2019 | $282.8M | $188.3M | $412.2M | +55% |
| 2018 | $182.7M | $163.7M | $356.1M | −33% |
| 2017 | $271.8M | $76.4M | $552.7M | −11% |
| 2016 | $304.6M | $205.6M | $904.9M | −49% |
| 2015 | $593.8M | $593.8M | $2.8B | −74% |
| 2014 | $2.3B | $1.8B | $4.1B | +24% |
| 2013 | $1.9B | $588.6M | $2.4B | +227% |
| 2012 | $567.7M | $268.5M | $578.2M | +73% |
| 2011 | $328.3M | $314.3M | $496.4M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Mannkind's size, closest first, today.
| Company | Market cap |
|---|---|
| MNKDMannkind | $1B |
| AMPHAmphastar Pharmaceuticals | $1.1B |
| OMEROmeros | $1.2B |
| ABUSArbutus Biopharma | $831M |
| COLLCollegium Pharmaceutical | $747.5M |
| PCRXPacira BioSciences | $1.5B |
| ANABAnaptysbio | $1.5B |
| PAHCPhibro Animal Health | $1.6B |
| ANIPANI Pharmaceuticals | $1.7B |
| CRMDCorMedix | $611.9M |
| ZVRAZevra Therapeutics | $582.6M |
| Peer median | $1.1B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Mannkind
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.